Lung Clearance Index as a Screening Parameter of Pulmonary Impairment in Patients under Immune Checkpoint Therapy: A Pilot Study

Immune checkpoint blockade (ICB) has presented a breakthrough in the treatment of malignant tumors and increased the overall survival of patients with various tumor entities. ICB may also cause immune-related adverse events, such as pneumonitis or interstitial lung disease. The lung clearance index...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2024-05, Vol.16 (11), p.2088
Hauptverfasser:	Steinbach, Maya-Leonie C, Eska, Jakob, Weitzel, Julia, Görges, Alexandra R, Tietze, Julia K, Ballmann, Manfred
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Age Apoptosis Bacterial pneumonia Carbon monoxide Cell death Complications and side effects CTLA-4 protein Cytotoxicity Diagnosis Drug therapy Hemoglobin Immune checkpoint inhibitors Immune clearance Immunotherapy Inflammation Lung diseases Lungs Lymphocytes T Melanoma Metastases Metastasis Patients PD-1 protein Pilot projects Pneumonia Pneumonitis Pulmonary function tests Respiratory function Risk factors Squamous cell carcinoma Thorax
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!